RT Journal Article
SR Electronic
T1 Predicting patient-specific radiotherapy responses in head and neck cancer to personalize radiation dose fractionation
JF bioRxiv
FD Cold Spring Harbor Laboratory
SP 630806
DO 10.1101/630806
A1 Heiko Enderling
A1 Enakshi Sunassee
A1 Jimmy J. Caudell
YR 2019
UL http://biorxiv.org/content/early/2019/05/07/630806.abstract
AB Human papillomavirus (HPV) related oropharyngeal cancer (OPC) is one of the few types of cancers increasing in incidence. HPV+ OPC treatment with radiotherapy (RT) provides 75-95% five-year locoregional control (LRC). Why some but not all patients with similar clinical stage and molecular profile are controlled remains unknown. We propose the proliferation saturation index, PSI, as a mathematical modeling biomarker of tumor growth and RT response. The model predicts that patients with PSI<0.75 are likely to be cured by radiation, and that hyperfractionated radiation could improve response rates for patients with higher PSI that are predicted to fail standard of care RT. Prospective evaluation is currently ongoing.